Sygnature Chemical Services and Heptares Therapeutics Announce Contract Chemistry Collaboration

12-Oct-2009 - United Kingdom

Sygnature Chemical Services Ltd. and Heptares Therapeutics Ltd. announced that they have entered into a contract chemistry collaboration in drug discovery. Under the terms of the agreement, scientists from the two companies are working together to advance one of Heptares’ internal high-value GPCR programmes. Sygnature is providing synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as StaRs™, Stabilised Receptors).

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!